As such, I downgraded my rating on Interparfums into Sell. Analyst’s Disclosure: I/we have no stock, option or similar ...
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no ...
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback